Tech Center 1600 • Art Units: 1646 1674
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17161929 | CHO CELL EXPRESSED HET IL-15 | Non-Final OA | NOVARTIS AG |
| 17708660 | METHODS FOR TREATING IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNOSUPPRESSION | Final Rejection | Novo Nordisk A/S |
| 19254656 | CYTOKINE COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Zahav Bioscience LLC |
| 18358510 | CYTOKINE COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Zahav Bioscience LLC |
| 17741095 | DESIGNED IL-2 VARIANTS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17908415 | PROTEIN NANOPARTICLE DESIGN AND APPLICATION | Non-Final OA | Duke University |
| 18838513 | MASKED IL12 PROTEIN | Final Rejection | Tagworks Pharmaceuticals B.V. |
| 17927257 | LIQUID FORMULATION | Non-Final OA | HANMI PHARM CO., LTD. |
| 18481833 | Adenovirus armed with bispecific T cell activator | Final Rejection | AKAMIS BIO, INC. |
| 18351442 | COMPOSITIONS AND METHODS FOR SELECTIVE ELIMINATION AND REPLACEMENT OF HEMATOPOIETIC STEM CELLS | Non-Final OA | Poseida Therapeutics, Inc. |
| 18259309 | METHODS USING ANTI-SLC3A2 AUTOANTIBODIES AND SLC3A2 FOR DETECTION OF GLIOMA BRAIN TUMOR FROM PATIENT SERUM | Non-Final OA | Istanbul Üniversitesi |
| 18312245 | ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF | Final Rejection | Werewolf Therapeutics, Inc. |
| 18035249 | USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS | Non-Final OA | ethris GmbH |
| 18027675 | INTERFERON TAU FC-FUSION PROTEINS AND METHODS FOR TREATING CORONAVIRUS INFECTIONS | Non-Final OA | Southlake Pharmaceuticals, Inc. |
| 17909066 | LIVE-PATHOGEN-MIMETIC NANOPARTICLES BASED ON PATHOGEN CELL WALL SKELETON, AND PRODUCTION METHOD THEREOF | Final Rejection | Progeneer Inc. |
| 17981930 | LIGHT CHAIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE THEREOF | Final Rejection | Stephen D. Gillies |
| 17961397 | MULTI-LIGAND DRUG CONJUGATES AND USES THEREOF | Non-Final OA | COHERENT BIOPHARMA I, LIMITED |
| 17935690 | DEGRADER-ANTIBODY CONJUGATES AND METHODS OF USING SAME | Non-Final OA | Anglex, Inc. |
| 17819254 | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA | Non-Final OA | EIT Pharma, Inc. |
| 17760279 | TREATMENT OF CORONAVIRUS INFECTION WITH INTERFERON LAMBDA | Non-Final OA | EIT Pharma, Inc. |
| 17797208 | METHODS FOR PREVENTING AND REVERSING OPIOID ANALGESIC TOLERANCE IN SUBJECTS WITH CHRONIC PAIN | Final Rejection | The Reasearch Foundation for Suny |
| 17784186 | NOVEL INTERLEUKIN-15 (IL-15) FUSION PROTEINS AND USES THEREOF | Non-Final OA | Cugene Inc |
| 16356483 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS | Final Rejection | In3Bio Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy